INBX Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $57.9K.
Where they traded
Last open-market purchase: September 8, 2026 , by FORSYTH DOUGLAS .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| MANHARD KIMBERLY | Director | Sell | 500 | $105.05 | $52.5K | 7,500 −6.3% of holding | |
| MANHARD KIMBERLY | Director | Sell | 500 | $110.26 | $55.1K | 8,000 −5.9% of holding | |
| MANHARD KIMBERLY | Director | Sell | 500 | $111.78 | $55.9K | 8,500 −5.6% of holding | |
| MANHARD KIMBERLY | Director | Sell | 500 | $115.80 | $57.9K | 9,000 −5.3% of holding | |
| Lappe Mark 6 fills | Chief Executive Officer | Buy | 25,000 | $105.82 | $2.6M | 730,548 | |
| Kayyem Jon Faiz | Director | Buy | 5,000 | $113.52 | $567.6K | 424,360 | |
| FORSYTH DOUGLAS | Director | Buy | 2,500 | $114.65 | $286.6K | 227,064 | |
| MANHARD KIMBERLY | Director | Sell | 500 | $115.14 | $57.6K | 9,500 −5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.